Social Mediafor PharmaceuticalCompanies
Most pharmaceutical companies underuse social media, not because they doubt the reach but because an always-on channel in a regulated market creates two risks: an unapproved claim published live, and an adverse event reported in a comment and missed. Both are process problems with known fixes.
In short
Hibridge runs social media and digital content programmes for pharmaceutical and healthcare organisations, covering corporate and disease-awareness channels, HCP-targeted content, community management with adverse-event escalation, paid social, and the governance model that keeps a live channel inside the promotional code.
What we do
Social media in a regulated market, with the review trail built in.
Channel strategy and governance
What each channel is for, what can be said on it, who approves, and what happens when something unexpected appears.
Disease awareness and corporate content
Non-promotional education, corporate reputation and employer-brand content, produced in both languages.
HCP-facing content
Gated and targeted content for verified healthcare professionals, timed against the wider omnichannel plan.
Community management
Moderation with a set escalation path for adverse events and product complaints, agreed response times, and a full audit log.
Paid social
Targeting, creative and measurement inside platform policy for health advertisers, which is stricter and changes more often than most teams track.
Adverse event workflow
A documented, trained escalation route from first comment to your pharmacovigilance inbox, with timestamps that survive an audit.
Approach
How we keep a live channel safe
- 01
Frame
Code positions and a pre-approved response library agreed before the channel goes live.
- 02
Produce
Content batched and checked ahead of time, so publishing is scheduling, not approving.
- 03
Monitor
Moderation against a set escalation matrix, with logged timestamps.
- 04
Report
Engagement plus a compliance log: escalations raised, response times, actions taken.
Why it matters
Digital now takes the clear majority of healthcare and pharma advertising spend, and social has overtaken linear television. The channel mix has moved; governance is what lags.
76%
US healthcare and pharma digital ad spending reached US$24.8 billion in 2025, 76% of the sector’s total ad spend, and is forecast to reach 82% by 2027.
eMarketer, 2025
33,000+
In IQVIA’s 2025 survey of more than 33,000 healthcare professionals across 38 countries, individual face-to-face meetings accounted for 40% of stated channel preference, in-person conferences 16%, and email 15%, a post-pandemic peak for email.
IQVIA (ChannelDynamics, 33,000+ HCPs across 38 countries), 2025
Every figure names its publisher. Where a figure is organiser-reported or secondary, we say so.
Frequently asked questions
How do you handle adverse events reported in comments?
With an escalation route agreed with your pharmacovigilance team before launch: how to spot one, a response template, a set handover window, and a timestamped log. Moderators are trained on that route, not a generic one.
Can pharmaceutical companies run paid social in Egypt?
Yes, within both the local promotional code and the platform’s own health advertising rules, which limit targeting and creative separately from local law. Both have to be cleared, and platform rules change more often.
Do you produce Arabic content, or translate it?
Produce. Health content translated from English reads as translated, and performs that way. We write in Arabic and review it against the same code positions.
Related services